Correction: Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis.

Haesuk Park,Yoona Kim,Donghak Jeong,Mindie H Nguyen,Pauline Nguyen,Linda Henry,Edward Sheen,Joseph Hoang

doi:10.1371/journal.pone.0209715

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0196452.].

Highlights

Chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections remain two of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) globally
Compared to HCV patients, adjusted mortality hazard ratio was slightly lower in HBV patients
Recent studies in the United States (US), conducted using the Nationwide Inpatient Sample (NIS), found that HBV-infected patients incurred higher inpatient resource utilization and greater inpatient mortality when compared to patients hospitalized with chronic HCV infection or alcoholic liver disease. [6,7] due to the cross sectional nature of the data, event-level records not patient-level recordings, these prior studies could not capture if patients required additional hospitalizations or patients died somewhere else than in a hospital

Summary

Introduction

Chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections remain two of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) globally. [1] On the other hand, HBV is widespread throughout Asia, especially in China, and is a major cause of cirrhosis and its complications, including HCC in Asia.[2]. [6,7] due to the cross sectional nature of the data, event-level records not patient-level recordings, these prior studies could not capture if patients required additional hospitalizations or patients died somewhere else than in a hospital These studies are limited in that they reflect only liver-related utilization and deaths and represent national trends, which may not be applied to some states where high-risk populations are prevalent (e.g. Asian Americans with HBV).[6,7] additional studies with patient-level longitudinal analyses are necessary to understand the long-term clinical and economic outcomes of HBV and HCV.

Methods

Results

Conclusion